Tyler Laundon photo

STOCKS

Tyler Laundon

Editor,

Cabot Small-Cap Confidential

About Tyler

Tyler Laundon is chief analyst of the limited-subscription advisory, Cabot Small-Cap Confidential. He has spent his entire career managing, consulting and analyzing start-up and small-cap companies. His hands-on experience has taught Tyler that the development of a superior business model is the biggest factor in determining a company's long-term success. Accordingly, his research focuses on assessing the viability of management's growth strategies, trends in addressable markets and achievement of major developmental milestones.Tyler's small-cap portfolios favor a high allocation to stable, high growth companies, upon which he layers strategic purchases of higher risk, event-driven investments. He first began publishing his analysis of small-cap opportunities in 2009. Since 2012, he has led his subscribers into 10 doubles. Between 2012 and September, 2015 his small-cap recommendations generated cumulative returns of over 2,300%, including both winners and losers, and outperformed the Russell 2000 Index by an average of 28% per year.Prior to joining Cabot, Tyler founded and operated a small business for 15 years. He then worked as a consultant for start-up technology companies, as well as Vermont's largest health care institution. From 2009 to 2015, he was the chief analyst of growth stocks at Wyatt Investment Research, where his research spanned the full spectrum of the growth stock universe, from micro-cap start-ups to multi-national mega-caps.Tyler holds a B.S. and MBA from The University of Vermont, where he graduated Valedictorian. He has been a long-time contributor to the Wall Street's Best Investments, has been quoted by U.S. News & World Report, and has presented investing ideas and strategies for The Money Show and Bloomberg Markets LiveINSIGHTS.

Tyler's Articles

Small-cap stocks continue to underperform their larger peers, though the S&P 600 Small-Cap Index ETF (IJR) has been inching higher toward resistance at 110. It’s possible that with expectations for the first rate cut being pushed out to June (currently, subject to change) that my expected small-cap rally has been similarly delayed. In the meantime, I like Enovix Corp. (ENVX) as a buy, writes Tyler Laundon, editor of Cabot Small-Cap Confidential.
Small caps have had a volatile week, which we can blame on the CPI inflation report (Tuesday) and subsequent move in interest rates. That all said, if you just woke up from a two-week nap you wouldn’t notice much at all at the small-cap index level. Meanwhile, EverQuote (EVER) is our newest addition and continues to look fantastic, notes Tyler Laundon, editor of Cabot Small-Cap Confidential.
TransMedics Group (TMDX) is a small-cap MedTech company addressing the unmet market need for more and healthier organs for transplantation, specifically in the heart, lung, and liver markets. It’s not a stock for the faint of heart (no pun intended). But the reward versus risk profile is very attractive, counsels Tyler Laundon, editor of Cabot Small-Cap Confidential.
Crocs (CROX) is a Colorado-based footwear company that was founded in 2002 and has two well-known brands, Crocs and HEYDUDE. Analyst projections are conservative. But Crocs could do a lot better. If it does, the stock could be off to the races, shares Tyler Laundon, editor of Cabot Small-Cap Confidential.